Storelli, Loredana
Pagani, Elisabetta
Meani, Alessandro
Preziosa, Paolo
Filippi, Massimo
Rocca, Maria A. http://orcid.org/0000-0003-2358-4320
Funding for this research was provided by:
Fondazione Italiana Sclerosi Multipla (FISM 2019/BR/009, FISM2018/R/16)
Article History
Received: 24 January 2022
Revised: 23 March 2022
Accepted: 24 March 2022
First Online: 10 April 2022
Declarations
:
: L. Storelli, E. Pagani, and A. Meani have nothing to disclose. P. Preziosa received speaker honoraria from Biogen Idec, Novartis, Bristol Myers Squibb, Genzyme and ExceMED. He is supported by a senior research fellowship FISM—Fondazione Italiana Sclerosi Multipla—cod. 2019/BS/009 and financed or co-financed with the ‘5 per mille’ public funding. Prof. Filippi is Editor-in-Chief of the <i>Journal of Neurology</i>, Associate Editor of <i>Human Brain Mapping</i>, Associate Editor of <i>Radiology</i>, and Associate Editor of <i>Neurological Sciences</i>; received compensation for consulting services and/or speaking activities from Alexion, Almirall, Bayer, Biogen, Celgene, Eli Lilly, Genzyme, Merck-Serono, Novartis, Roche, Sanofi, Takeda, and Teva Pharmaceutical Industries; and receives research support from Biogen Idec, Merck-Serono, Novartis, Roche, Teva Pharmaceutical Industries, Italian Ministry of Health, Fondazione Italiana Sclerosi Multipla, and ARiSLA (Fondazione Italiana di Ricerca per la SLA). Prof. M.A. Rocca received speaker honoraria from Bayer, Biogen, Bristol Myers Squibb, Celgene, Genzyme, Merck Serono, Novartis, Roche, and Teva, and receives research support from the MS Society of Canada and Fondazione Italiana Sclerosi Multipla.
: The ethics committee of IRCCS Ospedale San Raffaele approved the research protocol and the study was conducted in accordance with the principles of the Declaration of Helsinki.